Latest Administration News

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

Eastern Metals is progressing its acquisition of Raptor Resources and has agreed to sell its Browns Reef Project, while planning a $4-5 million capital raise pending shareholder approval.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Group One Capital Limited has appointed Ross Patane as Managing Director and CEO, marking a strategic leadership transition with seasoned expertise at the helm.

Metal Bank Limited is advancing its Western Australia gold strategy with significant resource development at Livingstone and a binding agreement to acquire Hastings Technology Metals’ WA gold assets, while also progressing critical minerals projects in Queensland and Saudi Arabia.

Strike Resources advances its high-grade Apurímac Iron Ore Project amid political upheaval in Peru, while its Lithium Energy stake pushes forward with key acquisitions and exploration despite ASX suspension.

Evolution Energy Minerals has successfully raised A$1.75 million through a fully underwritten rights issue, accelerating its Chilalo Graphite Project timeline to first ore production by October 2027. The company is also advancing exploration at its Chikundo copper project while streamlining operations.

Challenger Gold Limited advances its Hualilan Gold Project with commissioning of the Casposo Toll Milling plant and key operational contracts, while Ecuador projects gain value following Lumina Gold’s takeover. A $30 million placement strengthens funding for upcoming milestones.

Challenger Gold Limited reported a solid cash position of A$27.7 million for Q3 2025, backed by strong financing activities and a funding runway exceeding five quarters. The company’s strategic financing arrangements underpin its ongoing exploration ambitions.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

DGR Global Limited’s Q3 2025 report reveals ongoing project development, strategic equity holdings, and complex legal proceedings shaping its resource company creation model.